In-depth analysis of the advantages of dasatinib tablets

In the pathogenesis of chronic myelogenous leukemia (CML), a key step is that the chimeric BCR-ABL gene derived from the Philadelphia chromosome encodes a fusion protein BCR-ABL with sustained active tyrosine kinase activity. Imatinib, as an inhibitor of BCR-ABL tyrosine kinase, has played an important role in significantly improving the prognosis of CML patients. However, although most patients respond well to imatinib, there are still some patients, especially those in the accelerated phase or blast phase, who do not respond to imatinib or experience disease progression.

Research on the resistance mechanism of imatinib has promoted the development of newBCR-ABL inhibitors, among which dasatinib has shown great potential. Its potency is approximately 300 times that of imatinib. Not only that, dasatinib can also effectively inhibit SRC family kinases. Following the introduction of dasatinib in clinical trials, preliminary data showed the drug had a favorable safety and tolerability profile in patients with CML. Importantly, the majority of imatinib-resistant patients achieved an objective response with dasatinib, although the durability of this response requires further studies to determine.

Recent studies have found that dasatinib also exhibits a strong inhibitory effect on imatinib-resistant protein tyrosine kinase (KIT) activation loop mutants. This effect can induce apoptosis in mast cells and leukemia cell lines expressing these mutations, providing a new strategy for the treatment of CML. In addition, preclinical data on the activity of dasatinib in several human solid tumor cell lines opens up new possibilities for its application beyond CML.